{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T01:00:16Z","timestamp":1792890016023,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s10147-022-02243-4","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T08:03:51Z","timestamp":1665043431000},"page":"1859-1866","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study)"],"prefix":"10.1007","volume":"27","author":[{"given":"Hiroshi","family":"Matsuoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1436-7482","authenticated-orcid":false,"given":"Takeshi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuyuki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Fukazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Kuramochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihisa","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Koda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the TAS CC4 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"issue":"6","key":"2243_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424","journal-title":"CA Cancer J Clin"},{"issue":"16","key":"2243_CR2","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1200\/jco.2014.59.7633","volume":"33","author":"MG Fakih","year":"2015","unstructured":"Fakih MG (2015) Metastatic colorectal cancer: current state and future directions. J Clin Oncol Off J Am Soc Clin Oncol 33(16):1809\u20131824. https:\/\/doi.org\/10.1200\/jco.2014.59.7633","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"2243_CR3","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol Off J Eur Soc Med Oncol ESMO 27(8):1386\u20131422. https:\/\/doi.org\/10.1093\/annonc\/mdw235","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO"},{"issue":"9863","key":"2243_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/s0140-6736(12)61900-x","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):303\u2013312. https:\/\/doi.org\/10.1016\/s0140-6736(12)61900-x","journal-title":"Lancet"},{"issue":"4","key":"2243_CR5","first-page":"545","volume":"13","author":"T Emura","year":"2004","unstructured":"Emura T, Murakami Y, Nakagawa F et al (2004) A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med 13(4):545\u2013549","journal-title":"Int J Mol Med"},{"issue":"20","key":"2243_CR6","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372(20):1909\u20131919. https:\/\/doi.org\/10.1056\/NEJMoa1414325","journal-title":"N Engl J Med"},{"issue":"9","key":"2243_CR7","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/S1470-2045(17)30425-4","volume":"18","author":"Y Kuboki","year":"2017","unstructured":"Kuboki Y, Nishina T, Shinozaki E et al (2017) TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1\/2 study. Lancet Oncol 18(9):1172\u20131181. https:\/\/doi.org\/10.1016\/S1470-2045(17)30425-4","journal-title":"Lancet Oncol"},{"issue":"1","key":"2243_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10147-020-01794-8","volume":"26","author":"Y Yoshida","year":"2021","unstructured":"Yoshida Y, Yamada T, Kamiyama H et al (2021) Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study. Int J Clin Oncol 26(1):111\u2013117. https:\/\/doi.org\/10.1007\/s10147-020-01794-8","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"2243_CR9","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.21873\/anticanres.12738","volume":"38","author":"Y Yoshida","year":"2018","unstructured":"Yoshida Y, Sakamoto R, Kajitani R et al (2018) Biweekly administration of TAS-102 for neutropenia prevention in patients with colorectal cancer. Anticancer Res 38(7):4367\u20134373. https:\/\/doi.org\/10.21873\/anticanres.12738","journal-title":"Anticancer Res"},{"issue":"3","key":"2243_CR10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.23922\/jarc.2018-043","volume":"3","author":"Y Yoshida","year":"2019","unstructured":"Yoshida Y, Yamada T, Matsuoka H et al (2019) A trial protocol of biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced\/recurrent colorectal cancer: a phase II multicenter clinical trial (the TAS-CC4 study). J Anus Rectum Colon 3(3):136\u2013141. https:\/\/doi.org\/10.23922\/jarc.2018-043","journal-title":"J Anus Rectum Colon"},{"issue":"12","key":"2243_CR11","doi-asserted-by":"publisher","first-page":"e1855","DOI":"10.1634\/theoncologist.2020-0643","volume":"25","author":"H Satake","year":"2020","unstructured":"Satake H, Kato T, Oba K et al (2020) Phase Ib\/II study of biweekly TAS-102 in combination with bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study). Oncologist 25(12):e1855\u2013e1863. https:\/\/doi.org\/10.1634\/theoncologist.2020-0643","journal-title":"Oncologist"},{"issue":"3","key":"2243_CR12","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/s1470-2045(19)30827-7","volume":"21","author":"P Pfeiffer","year":"2020","unstructured":"Pfeiffer P, Yilmaz M, M\u00f6ller S et al (2020) TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol 21(3):412\u2013420. https:\/\/doi.org\/10.1016\/s1470-2045(19)30827-7","journal-title":"Lancet Oncol"},{"issue":"1","key":"2243_CR13","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1186\/s12885-019-6475-6","volume":"19","author":"D Kotani","year":"2019","unstructured":"Kotani D, Kuboki Y, Horasawa S et al (2019) Retrospective cohort study of trifluridine\/tipiracil (TAS-102) plus bevacizumab versus trifluridine\/tipiracil monotherapy for metastatic colorectal cancer. BMC Cancer 19(1):1253\u20131253. https:\/\/doi.org\/10.1186\/s12885-019-6475-6","journal-title":"BMC Cancer"},{"key":"2243_CR14","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0541","author":"H Fujii","year":"2019","unstructured":"Fujii H, Matsuhashi N, Kitahora M et al (2019) Bevacizumab in combination with TAS-102 improves clinical outcomes in patients with refractory metastatic colorectal cancer: a retrospective study. Oncologist Theoncologist. https:\/\/doi.org\/10.1634\/theoncologist.2019-0541","journal-title":"Oncologist Theoncologist"},{"issue":"4","key":"2243_CR15","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3892\/mco.2019.1899","volume":"11","author":"N Matsuhashi","year":"2019","unstructured":"Matsuhashi N, Takahashi T, Fujii H et al (2019) Combination chemotherapy with TAS-102 plus bevacizumab in salvage-line treatment of metastatic colorectal cancer: a single-center, retrospective study examining the prognostic value of the modified Glasgow Prognostic Score in salvage-line therapy of metastatic colorectal cancer. Mol Clin Oncol 11(4):390\u2013396. https:\/\/doi.org\/10.3892\/mco.2019.1899","journal-title":"Mol Clin Oncol"},{"key":"2243_CR16","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.74.3245","author":"J Xu","year":"2017","unstructured":"Xu J, Kim TW, Shen L et al (2017) Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study. J Clin Oncol Off J Am Soc Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2017.74.3245","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"33","key":"2243_CR17","doi-asserted-by":"publisher","first-page":"5326","DOI":"10.1200\/jco.2008.16.3212","volume":"26","author":"A Grothey","year":"2008","unstructured":"Grothey A, Sugrue MM, Purdie DM et al (2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol Off J Am Soc Clin Oncol 26(33):5326\u20135334. https:\/\/doi.org\/10.1200\/jco.2008.16.3212","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"2243_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna J, Sastre J, Arnold D et al (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14(1):29\u201337. https:\/\/doi.org\/10.1016\/s1470-2045(12)70477-1","journal-title":"Lancet Oncol"},{"issue":"7","key":"2243_CR19","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.3633","volume":"23","author":"A Grothey","year":"2014","unstructured":"Grothey A, Flick ED, Cohn AL et al (2014) Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. Pharmacoepidemiol Drug Saf 23(7):726\u2013734. https:\/\/doi.org\/10.1002\/pds.3633","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"2243_CR20","doi-asserted-by":"publisher","first-page":"1000093","DOI":"10.1016\/j.esmoop.2021.100093","volume":"6","author":"T Takahashi","year":"2021","unstructured":"Takahashi T, Yamazaki K, Oki E et al (2021) Phase II study of trifluridine\/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7. ESMO Open 6(2):1000093","journal-title":"ESMO Open"},{"issue":"1","key":"2243_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1634\/theoncologist.2017-0275","volume":"23","author":"T Moriwaki","year":"2018","unstructured":"Moriwaki T, Fukuoka S, Taniguchi H et al (2018) Propensity score analysis of regorafenib versus trifluridine\/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): a Japanese Society for Cancer of the colon and rectum multicenter observational study. Oncologist 23(1):7\u201315. https:\/\/doi.org\/10.1634\/theoncologist.2017-0275","journal-title":"Oncologist"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-022-02243-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-022-02243-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-022-02243-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T00:01:20Z","timestamp":1669420880000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-022-02243-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2243"],"URL":"https:\/\/doi.org\/10.1007\/s10147-022-02243-4","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,6]]},"assertion":[{"value":"1 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Suguru Hasegawa has received research funding from Taiho Pharmaceutical Industry and Takeda Pharmaceutical. Hidekazu Kuramochi has received scholarship donations from Taiho Pharmaceutical Industry and Chugai Pharmaceutical. The other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}